141 related articles for article (PubMed ID: 15304385)
1. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Yee KW; Schittenhelm M; O'Farrell AM; Town AR; McGreevey L; Bainbridge T; Cherrington JM; Heinrich MC
Blood; 2004 Dec; 104(13):4202-9. PubMed ID: 15304385
[TBL] [Abstract][Full Text] [Related]
2. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
3. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Schittenhelm MM; Kampa KM; Yee KW; Heinrich MC
Cell Cycle; 2009 Aug; 8(16):2621-30. PubMed ID: 19625780
[TBL] [Abstract][Full Text] [Related]
4. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
O'Farrell AM; Foran JM; Fiedler W; Serve H; Paquette RL; Cooper MA; Yuen HA; Louie SG; Kim H; Nicholas S; Heinrich MC; Berdel WE; Bello C; Jacobs M; Scigalla P; Manning WC; Kelsey S; Cherrington JM
Clin Cancer Res; 2003 Nov; 9(15):5465-76. PubMed ID: 14654525
[TBL] [Abstract][Full Text] [Related]
5. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.
Levis M; Pham R; Smith BD; Small D
Blood; 2004 Aug; 104(4):1145-50. PubMed ID: 15126317
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of
Ueno Y; Mori M; Kamiyama Y; Saito R; Kaneko N; Isshiki E; Kuromitsu S; Takeuchi M
Oncotarget; 2019 Apr; 10(26):2530-2545. PubMed ID: 31069015
[TBL] [Abstract][Full Text] [Related]
7. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Schittenhelm MM; Yee KW; Tyner JW; McGreevey L; Haley AD; Town A; Griffith DJ; Bainbridge T; Braziel RM; O'Farrell AM; Cherrington JM; Heinrich MC
Leukemia; 2006 Nov; 20(11):2008-14. PubMed ID: 16990784
[TBL] [Abstract][Full Text] [Related]
8. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
9. Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells.
Rörby E; Adolfsson J; Hultin E; Gustafsson T; Lotfi K; Cammenga J; Jönsson JI
Exp Hematol Oncol; 2021 Feb; 10(1):7. PubMed ID: 33531064
[TBL] [Abstract][Full Text] [Related]
10. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
[TBL] [Abstract][Full Text] [Related]
11. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
[TBL] [Abstract][Full Text] [Related]
12. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Wu M; Li L; Hamaker M; Small D; Duffield AS
Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
[TBL] [Abstract][Full Text] [Related]
14. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
15. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H
Leukemia; 2016 May; 30(5):1025-32. PubMed ID: 26686245
[TBL] [Abstract][Full Text] [Related]
16. NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.
Kowolik CM; Lin M; Xie J; Overman LE; Horne DA
Oncotarget; 2016 Dec; 7(52):86186-86197. PubMed ID: 27863389
[TBL] [Abstract][Full Text] [Related]
17. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
[TBL] [Abstract][Full Text] [Related]
19. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
[TBL] [Abstract][Full Text] [Related]
20. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
